Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemoprophylaxis for HIV Prevention in Men.

Trial Profile

Chemoprophylaxis for HIV Prevention in Men.

Phase of Trial: Phase III

Latest Information Update: 03 Feb 2018

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications Herpes simplex virus type 2 infections; HIV infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms iPrEX
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 Feb 2018 Results (n=498) assessing effects of TDF/FTC on lipids and body composition in participants in a blinded placebo controlled iPrEP trial, were published in the Clinical Infectious Diseases.
    • 29 Aug 2016 Results of this and other four studies published in the Antimicrobial Agents and Chemotherapy (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top